Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Tan Sheet

Executive Summary

Cepacol Fizzlers target kids' sore throats: Combe Inc. extends its benzocaine sore throat relief line into a grape-flavored pediatric product that rapidly dissolves on the tongue. Cepacol Fizzlers launched Sept. 1, the White Plains, N.Y., company said, and is labeled for use by patients ages 5 to 12. A box of 12 tablets retails for a suggested price of $5.99 at major food, drug and mass market stores

You may also be interested in...



In Brief

Novartis makes OTC exec change following recall and plant shutdown; Prestige Brands adopts plan to deter Genomma takeover bid; Pfizer scoops up Emergen-C maker Alacer; CSPI threatens Amway with Nutrilite suit; more news In Brief.

Developing Antitussive Alternatives To DXM Would Offset Commercial Risk

Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk

Developing Antitussive Alternatives To DXM Would Offset Commercial Risk

Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel